ZVRA Q2 2021 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$559M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+73.5% YoY

Gross Profit

$11M91.7% margin

Operating Income

$6M48.7% margin

Net Income

$6M51.8% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$318,000

Balance Sheet

Total Assets

$139M

Total Liabilities

$8M

Stockholders' Equity

$131M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$7M	+73.5%
Gross Profit	$11M	$6M	+75.3%
Operating Income	$6M	$3M	+125.0%
Net Income	$6M	$859,000	+622.1%